G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
September 15 2021 - 5:45AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that it will hire and train a 15-person
oncology sales force to supplement the Boehringer Ingelheim
oncology commercial team. The expansion will allow G1 to target top
tier accounts in order to accelerate sales activities and help
maximize the adoption of COSELA™ (trilaciclib).
The new G1 sales representatives will supplement the existing
Boehringer Ingelheim oncology commercial team. G1 entered into a
three-year co-promotion agreement with Boehringer Ingelheim to
collaborate on the commercialization of COSELA for its first
indication in ES-SCLC. (press release)
“This additional sales force will allow us to expand the reach
into our top tier accounts, who treat up to 50 percent of patients
diagnosed with small cell lung cancer,” said Andrew Perry, G1’s
Chief Commercial Officer. “COSELA is the only multilineage
myeloprotection therapy developed to proactively reduce the risk of
some of the dangerous side effects of chemotherapy in certain
patients. We envision working closely with our partners at BI to
maximize demand and adoption of this important medicine among these
top accounts, as we seek to ensure the availability of COSELA to as
many appropriate patients living with ES-SCLC as possible.”
On September 9, 2021, the G1 Board of Directors adopted the G1
Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive
Plan (the “Plan”). There are 500,000 shares of common stock
reserved under the Plan to be used exclusively for grants of awards
to sales force individuals and support staff that were not
previously employees or directors of G1, as an inducement material
to the individuals’ entry into employment with G1 within the
meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Plan
was approved by the Board of Directors without stockholder approval
pursuant to Rule 5635(c)(4), and the terms and conditions of the
Plan are substantially similar to G1’s stockholder-approved 2017
Equity Incentive Plan, as amended.
About COSELA™ (trilaciclib) for Injection
COSELA (trilaciclib) was approved by the U.S. Food and Drug
Administration on February 12, 2021.
IndicationCOSELA™ (trilaciclib) is indicated to
decrease the incidence of chemotherapy-induced myelosuppression in
adult patients when administered prior to a
platinum/etoposide-containing regimen or topotecan-containing
regimen for extensive-stage small cell lung cancer.
Important Safety InformationCOSELA is
contraindicated in patients with a history of serious
hypersensitivity reactions to trilaciclib.
Warnings and precautions include injection-site reactions
(including phlebitis and thrombophlebitis), acute drug
hypersensitivity reactions, interstitial lung disease
(pneumonitis), and embryo-fetal toxicity.
The most common adverse reactions (>10%) were fatigue,
hypocalcemia, hypokalemia, hypophosphatemia, aspartate
aminotransferase increased, headache, and pneumonia.
This information is not comprehensive. Please click here for
full Prescribing Information.
https://www.g1therapeutics.com/cosela/pi/
To report suspected adverse reactions, contact G1 Therapeutics
at 1-800-790-G1TX or call FDA at 1-800-FDA-1088 or visit
www.fda.gov/medwatch.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that
improve the lives of those affected by cancer, including the
Company’s first commercial product, COSELA™ (trilaciclib). G1 has a
deep clinical pipeline and is executing a tumor-agnostic
development plan evaluating COSELA in a variety of solid tumors,
including colorectal, breast, lung, and bladder cancers. G1
Therapeutics is based in Research Triangle Park, N.C. For
additional information, please visit www.g1therapeutics.com and
follow us on Twitter @G1Therapeutics.
G1 Therapeutics™ and the G1 Therapeutics logo and COSELA™ and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this press release include, but are
not limited to, those relating to the Company’s ability to
accelerate sales activities and maximize reach into top tier
accounts. Each of these forward-looking statements involves risks
and uncertainties. Factors that may cause the company’s actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
the company’s filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained therein
and include, but are not limited to, the company’s dependence on
the commercial success of COSELA; the development and
commercialization of new drug products is highly competitive; the
company’s ability to complete clinical trials for, obtain approvals
for and commercialize any of its product candidates; the company’s
initial success in ongoing clinical trials may not be indicative of
results obtained when these trials are completed or in later stage
trials; the inherent uncertainties associated with developing new
products or technologies and operating as a development-stage
company; and market conditions. Except as required by law, the
company assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Will RobertsVice President, Investor Relations & Corporate
Communications919-907-1944 wroberts@g1therapeutics.com
Rebecca LevineDirector, Corporate Communications and Public
Relations(919) 667-8711 rlevine@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Apr 2024 to May 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From May 2023 to May 2024